

Cilostazol Aqueous Solubility as a Function of Solubilizer Concentration
Simulated Intestinal Fluid w/o Enzyme, pH 6.8, 37°C




Figure 1

Cilostazol and Solubilizer Release from Example 2-1
 USP Apparatus I, 100 rpm; 37°C;
 1000 ml SGF w/o enzyme + 0.275% w/v sodium dodecyl sulfate




Figure 2

Release of Solubilizers and Enhancement of Cilostazol Solubility from Ex. 3-1
 Extended Release Tester, 10 rpm, 37°C;
 0-2h: 100 ml SGF w/o enzyme, 2+ h: 100 ml SIF w/o enzyme (pH 6.8)




Figure 3

Release of Cilostazol from Examples 6-1 and 6-2
USP App. I, 100 rpm; 37°C, 1000 ml SIF w/o enzyme (pH 6.8)




Figure 4

Release of Carvedilol and Solubilizer from Example 9-1 and 9-2
 USP Apparatus I, 100 rpm, $37.0 \pm 0.5^\circ\text{C}$;
 0-2 h: 1,000 ml SGF (pH 1.2); 2+h: 1,000 ml SIF (pH 6.8)




Figure 5

Release of Carvedilol from Example 10-1 and Comparator 10-1
 Extended release tester; 10 rpm, 37.0±0.1°C, 100 ml




Figure 6




Figure 7

Extended Release of Zafirlukast in 250 ml SGF (pH1.2) for 2 Hours and Subsequently in 250 ml SIF (pH 6.8) for 22 Hours at 37°C (USP I, 100 rpm)




Figure 8

Release of Zafirlukast from Example 12-4 and 12-8
USP Apparatus I; 100 rpm, 37.0±0.1 °C;
0-2h: 250 ml SGF, 2+h: 250 ml SIF (pH 6.8)




Figure 9

Release of Pioglitazone from Example 15-1, 15-2, and 15-3
USP Apparatus II; 100 rpm, 37.0±0.1°C, 250 ml SIF (pH 6.8)




Figure 10